Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Total Liabilities
Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has total liabilities worth CN¥82.76 Million CNY (≈ $12.11 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 688091 net asset momentum to track the company's year-over-year net asset growth rate.
Shanghai Yizhong Pharmaceutical Co Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 688091 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Zhidemai Technology
SHE:300785
|
China | CN¥541.93 Million |
|
Elemental Royalties Corp
V:ELE
|
Canada | CA$126.90 Million |
|
Eastcompeace Technology Co Ltd
SHE:002017
|
China | CN¥1.19 Billion |
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
China | CN¥7.83 Billion |
|
Chengdu Leejun Industrial Co Ltd
SHE:002651
|
China | CN¥830.94 Million |
|
361 Degrees International Limited
F:36L
|
Germany | €3.61 Billion |
|
Harbin Electric Coporation Jiamusi Electric Machine Co Ltd
SHE:000922
|
China | CN¥4.54 Billion |
|
Beijing Jiuzhou Yi Gui Environmental Technology Co. Ltd.
SHG:688485
|
China | CN¥141.84 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Shanghai Yizhong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai Yizhong Pharmaceutical Co Ltd (688091) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Yizhong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total liabilities of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥42.97 Million ≈ $6.29 Million |
-60.40% |
| 2023-12-31 | CN¥108.52 Million ≈ $15.88 Million |
+206.43% |
| 2022-12-31 | CN¥35.42 Million ≈ $5.18 Million |
+41.54% |
| 2021-12-31 | CN¥25.02 Million ≈ $3.66 Million |
+63.50% |
| 2020-12-31 | CN¥15.30 Million ≈ $2.24 Million |
+24.79% |
| 2019-12-31 | CN¥12.26 Million ≈ $1.79 Million |
-28.49% |
| 2018-12-31 | CN¥17.15 Million ≈ $2.51 Million |
+6.02% |
| 2017-12-31 | CN¥16.17 Million ≈ $2.37 Million |
-- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more